Open AccessClinical outcomes and metastatic behavior between de novo versus recurrent HER2-positive metastatic breast cancer: A 17-year single-institution cohort study at Taipei Veterans General Hospital
Author(s) -
Hui Cheng,
YiFang Tsai,
ChiCheng Huang,
PeiJu Lien,
Yuling Wang,
Chih-Yi Hsu,
Yen-Jen Chen,
Chunyu Liu,
TaChung Chao,
YuanYung Lin,
Chin-Jung Feng,
Jan-Wei Chiu,
GarYang Chau,
LingMing Tseng
Publication year - 2022
Publication title -
journal of the chinese medical association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.535
H-Index - 42
eISSN - 1728-7731
pISSN - 1726-4901
DOI - 10.1097/jcma.0000000000000622
Subject(s) - medicine , metastatic breast cancer , hazard ratio , proportional hazards model , cohort , oncology , breast cancer , stage (stratigraphy) , progression free survival , cancer , chemotherapy , confidence interval , biology , paleontology
To assess the clinical outcomes and metastatic behavior between de novo versus recurrent human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) based on a single-institution database in Taiwan.